Modality
Gene Therapy
MOA
CD47i
Target
WRN
Pathway
RNA Splicing
Gastric Ca
Development Pipeline
Preclinical
Jun 2022
→ Jul 2028
PreclinicalCurrent
NCT06249805
507 pts·Gastric Ca
2022-06→2028-07·Terminated
507 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-212.3y awayInterim· Gastric Ca
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Termina…
Catalysts
Interim
2028-07-21 · 2.3y away
Gastric Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06249805 | Preclinical | Gastric Ca | Terminated | 507 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Lisorapivir | Takeda | Preclinical | WRN |